The Long Run with Luke Timmerman
Timmerman Report
"The Long Run"
Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous.
Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous.
Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
Episodes
Mentioned books
Oct 2, 2018 • 1h 9min
Ep28: Sabah Oney
Sabah Oney on becoming a scientific business executive.
Sep 18, 2018 • 58min
Ep27: Amy Abernethy
Amy Abernethy on making EHRs useful for drug development.
Sep 5, 2018 • 55min
Ep26: Meg Tirrell
Meg Tirrell on covering biotech on TV.
Aug 21, 2018 • 1h 3min
Ep25: Thong Le
Thong Le on building startups to suit pharma needs.
Aug 7, 2018 • 59min
Ep24: Ankit Mahadevia
Ankit Mahadevia on the antibiotic opportunity
Jul 24, 2018 • 1h 3min
Ep23: Chris Garabedian
Chris Garabedian on the "middle market" of biotech VC.
Jul 9, 2018 • 1h 5min
Ep22: Vicki Sato (Take 2)
Vicki Sato on her career in biotech.
Jun 21, 2018 • 1h 2min
Ep21: Tony Coles
Tony Coles on neurodegenerative drug discovery and inclusive leadership.
Jun 4, 2018 • 1h 4min
Ep20: Rob Perez
Ep20: Rob Perez by Timmerman Report
May 9, 2018 • 1h 5min
Ep19: Chip Clark
Ep19: Chip Clark by Timmerman Report


